Aarti Pharmalabs Limited has officially announced its quarterly earnings conference call to discuss Q3FY26 financial results. The pharmaceutical company issued a formal intimation to stock exchanges on February 02, 2026, under Regulation 30 of the SEBI (LODR) Regulations 2015.

Conference Call Details

The earnings conference call has been scheduled as a group meeting for investors and analysts. The company will host the session to provide comprehensive insights into its third quarter performance for fiscal year 2026.

Management Participation

The earnings call will feature key leadership members who will present the quarterly results and address participant queries. The company has confirmed participation from its senior management team.

Access Information

The company has provided multiple access options for participants, including domestic dial-in numbers and international toll-free lines. Participants can pre-register to avoid waiting queues through the DiamondPass registration link.

Domestic Access Numbers

International Toll-Free Access

Regulatory Compliance

The earnings call announcement was made in compliance with regulatory requirements, with the company informing both BSE Limited (Scrip Code: 543748) and National Stock Exchange of India Limited (Symbol: AARTIPHARM). The intimation was signed by Company Secretary and Legal Head Jeevan Mondkar on February 02, 2026.

For additional information regarding the conference call, participants can contact Candice Pareira, AVP Research at Dolat Capital Market Pvt. Ltd., or Zain Gulam Hussain, Research Associate at the same firm.

Aarti Pharmalabs Limited has announced a key leadership appointment in its research and development division. The pharmaceutical company has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D and Senior Management Personnel, effective January 01, 2026.

Board Approval and Regulatory Compliance

The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee. The company made this disclosure pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The key details of the appointment are structured as follows:

Professional Background and Qualifications

Dr. Bandichhor brings substantial expertise to his new role, with 25 years of rich experience in API-R&D and Process Chemistry. His academic credentials include:

• M.Sc. (Chemistry) from University of Lucknow
• M.Sc. (Tech) in Pharmaceutical Chemistry from University of Lucknow
• Ph.D. in Chemistry from CDRI, University of Lucknow
• Additional studies at University of Regensburg, Germany through a German fellowship program

International Training and Experience

The new Chief Scientific Officer has undergone extensive postdoctoral training at three prestigious international institutions:

• University of Regensburg, Germany
• University of Pennsylvania, USA
• Texas A&M University, College Station, USA

Prior to joining Aarti Pharmalabs Limited, Dr. Bandichhor was associated with Dr. Reddy's Laboratories in Hyderabad, where he gained valuable industry experience in pharmaceutical research and development.

Strategic Significance

This appointment reflects the company's commitment to strengthening its research and development capabilities. With Dr. Bandichhor's extensive experience in API-R&D and Process Chemistry, combined with his international exposure and academic background, the company is positioned to enhance its scientific research initiatives and innovation capabilities in the pharmaceutical sector.